Ifinatamab Deruxtecan Continues to Display Promising Goal Response Charges in Sufferers with Intensive-Stage Small Cell Lung Most cancers in IDeate-Lung01 Part 2 Trial By Investing.com
Goal response price of 54.8% seen with Daiichi Sankyo and Merck's ifinatamab…
GC Cell and Lukas Announce Strategic Cooperation Settlement to Collectively Faucet into the Modern Cell Remedy together with and past Korean and Taiwanese Market By Investing.com
YONGIN, South Korea, July 21, 2024 /PRNewswire/ -- GC Cell Company (hereinafter…
